US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BioAge Labs Inc.

8.65

-0.5200-5.67%

Post-market: 8.650.00000.00%19:42 EDT

Volume:492.87K

Turnover:4.30M

Market Cap:397.01M

PE:-3.65

High:9.07

Open:9.07

Low:8.60

Close:9.17

52wk High:25.96

52wk Low:4.68

Shares:45.90M

Float Shares:37.58M

Volume Ratio:1.15

T/O Rate:1.31%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3710

EPS(LYR):-2.2432

ROE:-28.21%

ROA:-18.47%

PB:1.06

PE(LYR):-3.86

Loading ...

Overview Company News Filings

Bioage Labs Q1 EPS $(0.52) Beats $(0.64) Estimate, Sales $2.772M Beat $1.083M Estimate

Benzinga Earnings

BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration

Bioage Labs Inc Q1 Collaboration Revenue USD 2.772 Million VS. Ibes Estimate USD 1.32 Million

THOMSON REUTERS

Bioage Labs Inc Q1 EPS USD -0.52

THOMSON REUTERS

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge hosts R&D Day webcast on BGE-102 NLRP3 inhibitor program

BioAge Labs announces annual shareholder meeting notice

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Geron (GERN)

BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating

BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2

BioAge Shares Rise on Positive Trial Data

BioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients

MT Newswires Live

Bioage Labs: Reports Positive Phase 1 Data for Bge-102

THOMSON REUTERS

Bioage Labs Inc - Phase 2 Cardiovascular Risk Trial to Initiate Mid-2026, Results Expected End 2026

THOMSON REUTERS

Bioage Labs Inc - Bge-102 Well Tolerated Across All Dose Levels

THOMSON REUTERS

Bioage Labs Inc - Bge-102 Achieves ≥85% Median Hscrp Reductions at 120 Mg and 60 Mg Doses in Obesity

THOMSON REUTERS

BioAge reports Phase 1 data for BGE-102, showing 85% hsCRP reduction

BioAge Labs to present at Needham Virtual Healthcare Conference

BioAge Labs CMO Paul D. Rubin disposes of common shares worth $0.2 million

Needham Initiates BioAge Labs at Buy With $50 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BIOA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BIOA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":8.65,"timestamp":1789070400000,"preClose":9.17,"halted":0,"volume":492865,"hourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.65,"latestTime":"19:42 EDT","volume":6520,"amount":56400.0837,"timestamp":1789083770374,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.05670665212649941,"floatShares":37575608,"shares":45896909,"eps":-2.371024,"marketStatus":"Not Yet Opened","change":-0.52,"latestTime":"09-10 16:00:00 EDT","open":9.07,"high":9.07,"low":8.6,"amount":4303190.021915,"amplitude":0.051254,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.371024,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":9.17,"preHourTrading":{"tag":"盘前","latestPrice":9.06,"preClose":9.17,"latestTime":"09:29 EDT","volume":240,"amount":2179.10808,"timestamp":1789046999999,"change":-0.11,"changeRate":-0.011996,"amplitude":0.045583},"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.65,"latestTime":"19:42 EDT","volume":6520,"amount":56400.0837,"timestamp":1789083770374,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.151653,"impliedVol":1.2171,"impliedVolPercentile":0.792},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIOA\",,,,,undefined,":{"symbol":"BIOA","floatShares":37575608,"roa":"-18.47%","roe":"-28.21%","lyrEps":-2.243207,"volumeRatio":1.151653,"shares":45896909,"dividePrice":0,"high":9.07,"amplitude":0.051254,"preClose":9.17,"low":8.6,"week52Low":4.68,"pbRate":"1.06","psRate":"38.34","week52High":25.955,"institutionHeld":0,"latestPrice":8.65,"eps":-2.371024,"divideRate":0,"volume":492865,"delay":0,"ttmEps":-2.371024,"open":9.07,"prevYearClose":13.23,"prevWeekClose":9.59,"prevMonthClose":9.5,"prevQuarterClose":24.51,"fiveDayClose":9.73,"twentyDayClose":10.48,"sixtyDayClose":19.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIOA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"BIOA","fiscalQuarterEnding":"2026/06","expectedEps":-0.65,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":-0.58},{"market":"US","date":"2026-05-08","symbol":"BIOA","fiscalQuarterEnding":"2026/03","expectedEps":-0.71,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-03-24","symbol":"BIOA","fiscalQuarterEnding":"2025/12","expectedEps":-0.83,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-06","symbol":"BIOA","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.56},{"market":"US","date":"2025-08-06","symbol":"BIOA","fiscalQuarterEnding":"2025/06","expectedEps":-0.56,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIOA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIOA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4444,"buy":0.3333,"hold":0.2222,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":9,"updateTime":1779940800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BIOA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BIOA","date":"2026-09-09","current":-3.648213,"percent":0.488706,"low":-14.88445,"twenty":-10.391619,"median":-4.342854,"eighty":-2.196347,"high":-1.532635,"avg":-5.902008,"sd":3.947255,"marketCap":431201460},"quantilePoints":[{"date":"2024-09-27","current":-10.065016,"twenty":-9.996853,"median":-9.894609,"eighty":-9.328936,"marketCap":625601139},{"date":"2024-10-04","current":-11.466752,"twenty":-11.453559,"median":-10.988513,"eighty":-9.962772,"marketCap":712727458},{"date":"2024-10-11","current":-11.290848,"twenty":-11.83725,"median":-11.290848,"eighty":-10.377246,"marketCap":701793959},{"date":"2024-10-18","current":-13.247909,"twenty":-12.852074,"median":-11.505231,"eighty":-10.913754,"marketCap":823437060},{"date":"2024-10-25","current":-13.708907,"twenty":-13.699687,"median":-12.032944,"eighty":-11.062173,"marketCap":852090807},{"date":"2024-10-31","current":-14.198716,"twenty":-13.910593,"median":-12.258321,"eighty":-11.163318,"marketCap":882535413},{"date":"2024-11-08","current":-10.411209,"twenty":-13.841443,"median":-12.631325,"eighty":-11.163318,"marketCap":738550334},{"date":"2024-11-15","current":-9.850761,"twenty":-13.741177,"median":-12.203351,"eighty":-10.879672,"marketCap":698793259},{"date":"2024-11-22","current":-9.318711,"twenty":-13.704297,"median":-11.736106,"eighty":-10.071646,"marketCap":661050728},{"date":"2024-11-29","current":-9.500638,"twenty":-13.685857,"median":-11.456511,"eighty":-9.850761,"marketCap":673956274},{"date":"2024-12-06","current":-9.283336,"twenty":-13.657045,"median":-11.290848,"eighty":-9.500638,"marketCap":658541317},{"date":"2024-12-13","current":-2.319571,"twenty":-13.258776,"median":-11.073716,"eighty":-9.298497,"marketCap":164545707},{"date":"2024-12-20","current":-2.612676,"twenty":-13.247909,"median":-10.411209,"eighty":-9.141838,"marketCap":185337975},{"date":"2024-12-27","current":-2.971476,"twenty":-13.224859,"median":-10.152544,"eighty":-7.606575,"marketCap":210790579},{"date":"2025-01-03","current":-2.809763,"twenty":-13.09117,"median":-10.065016,"eighty":-3.032119,"marketCap":199318983},{"date":"2025-01-10","current":-2.572247,"twenty":-12.858367,"median":-9.894609,"eighty":-2.886577,"marketCap":182470076},{"date":"2025-01-17","current":-2.54698,"twenty":-12.632478,"median":-9.680039,"eighty":-2.714757,"marketCap":180677639},{"date":"2025-01-24","current":-2.678371,"twenty":-12.552115,"median":-9.568861,"eighty":-2.625815,"marketCap":189998311},{"date":"2025-01-31","current":-2.415588,"twenty":-12.247327,"median":-9.318711,"eighty":-2.600547,"marketCap":171356967},{"date":"2025-02-07","current":-2.309464,"twenty":-12.16927,"median":-9.263122,"eighty":-2.51868,"marketCap":163828732},{"date":"2025-02-14","current":-2.284196,"twenty":-12.012055,"median":-9.141838,"eighty":-2.417609,"marketCap":162036295},{"date":"2025-02-21","current":-2.223554,"twenty":-11.928501,"median":-8.818412,"eighty":-2.37516,"marketCap":157734447},{"date":"2025-02-28","current":-2.208393,"twenty":-11.54371,"median":-3.087708,"eighty":-2.319571,"marketCap":156658985},{"date":"2025-03-07","current":-2.269035,"twenty":-11.466752,"median":-2.971476,"eighty":-2.294303,"marketCap":160960833},{"date":"2025-03-14","current":-2.122483,"twenty":-11.446271,"median":-2.893147,"eighty":-2.269035,"marketCap":150564699},{"date":"2025-03-21","current":-2.208204,"twenty":-11.43377,"median":-2.779442,"eighty":-2.233661,"marketCap":157023162},{"date":"2025-03-28","current":-1.956126,"twenty":-11.290848,"median":-2.7188,"eighty":-2.233661,"marketCap":139098143},{"date":"2025-04-04","current":-1.714131,"twenty":-11.203915,"median":-2.693532,"eighty":-2.213447,"marketCap":121890125},{"date":"2025-04-11","current":-1.729255,"twenty":-11.131435,"median":-2.645523,"eighty":-2.198286,"marketCap":122965626},{"date":"2025-04-17","current":-1.890585,"twenty":-11.039085,"median":-2.589935,"eighty":-2.192221,"marketCap":134437638},{"date":"2025-04-25","current":-2.117456,"twenty":-10.879672,"median":-2.54698,"eighty":-2.170997,"marketCap":150570155},{"date":"2025-05-02","current":-2.087206,"twenty":-10.498085,"median":-2.486337,"eighty":-2.155781,"marketCap":148419153},{"date":"2025-05-09","current":-2.073948,"twenty":-10.229442,"median":-2.420641,"eighty":-2.117456,"marketCap":147343652},{"date":"2025-05-16","current":-1.927611,"twenty":-10.158835,"median":-2.377687,"eighty":-2.112406,"marketCap":136947141},{"date":"2025-05-23","current":-2.038626,"twenty":-10.109042,"median":-2.344838,"eighty":-2.086198,"marketCap":144834149},{"date":"2025-05-30","current":-2.008349,"twenty":-10.078276,"median":-2.334731,"eighty":-2.073148,"marketCap":142683147},{"date":"2025-06-06","current":-2.24047,"twenty":-9.99928,"median":-2.314518,"eighty":-2.051746,"marketCap":159174164},{"date":"2025-06-13","current":-2.2657,"twenty":-9.918948,"median":-2.294303,"eighty":-2.064674,"marketCap":160966666},{"date":"2025-06-20","current":-2.215239,"twenty":-9.87707,"median":-2.284196,"eighty":-2.072748,"marketCap":157381662},{"date":"2025-06-27","current":-2.200101,"twenty":-9.785504,"median":-2.271562,"eighty":-2.073948,"marketCap":156306161},{"date":"2025-07-03","current":-2.159732,"twenty":-9.684587,"median":-2.26468,"eighty":-2.075591,"marketCap":153438158},{"date":"2025-07-11","current":-2.361576,"twenty":-9.665383,"median":-2.263661,"eighty":-2.08254,"marketCap":167778173},{"date":"2025-07-18","current":-2.422129,"twenty":-9.609795,"median":-2.271562,"eighty":-2.08404,"marketCap":172080177},{"date":"2025-07-25","current":-2.371668,"twenty":-9.500638,"median":-2.280838,"eighty":-2.084673,"marketCap":168495173},{"date":"2025-08-01","current":-2.220285,"twenty":-9.464253,"median":-2.280838,"eighty":-2.088197,"marketCap":157740162},{"date":"2025-08-08","current":-1.959737,"twenty":-9.314668,"median":-2.269035,"eighty":-2.084673,"marketCap":154872159},{"date":"2025-08-15","current":-2.023247,"twenty":-9.295465,"median":-2.262157,"eighty":-2.074957,"marketCap":159891165},{"date":"2025-08-22","current":-2.041393,"twenty":-9.27525,"median":-2.258928,"eighty":-2.064982,"marketCap":161325166},{"date":"2025-08-29","current":-2.177486,"twenty":-9.225726,"median":-2.244642,"eighty":-2.064982,"marketCap":172080177},{"date":"2025-09-05","current":-2.136658,"twenty":-9.156998,"median":-2.24047,"eighty":-2.068612,"marketCap":168853674},{"date":"2025-09-12","current":-2.227387,"twenty":-9.141838,"median":-2.24047,"eighty":-2.071948,"marketCap":176023681},{"date":"2025-09-19","current":-2.368016,"twenty":-8.95182,"median":-2.24047,"eighty":-2.073948,"marketCap":187137193},{"date":"2025-09-26","current":-2.368016,"twenty":-8.818412,"median":-2.24047,"eighty":-2.073948,"marketCap":187137193},{"date":"2025-10-03","current":-2.676493,"twenty":-8.732502,"median":-2.244642,"eighty":-2.078994,"marketCap":211515218},{"date":"2025-10-10","current":-2.472354,"twenty":-3.102868,"median":-2.258928,"eighty":-2.082165,"marketCap":195382701},{"date":"2025-10-17","current":-2.318115,"twenty":-3.072547,"median":-2.260654,"eighty":-2.08404,"marketCap":183193689},{"date":"2025-10-24","current":-3.606461,"twenty":-3.072547,"median":-2.2657,"eighty":-2.08404,"marketCap":285007794},{"date":"2025-10-31","current":-3.50666,"twenty":-3.483977,"median":-2.271562,"eighty":-2.087206,"marketCap":277120786},{"date":"2025-11-07","current":-3.533398,"twenty":-3.483977,"median":-2.280838,"eighty":-2.091294,"marketCap":267799776},{"date":"2025-11-14","current":-3.65216,"twenty":-3.543352,"median":-2.287377,"eighty":-2.091294,"marketCap":276800885},{"date":"2025-11-21","current":-4.063738,"twenty":-3.690007,"median":-2.299357,"eighty":-2.092162,"marketCap":307994767},{"date":"2025-11-28","current":-4.489508,"twenty":-3.899107,"median":-2.309042,"eighty":-2.092231,"marketCap":340264301},{"date":"2025-12-05","current":-4.967317,"twenty":-4.069415,"median":-2.318115,"eighty":-2.105866,"marketCap":376477888},{"date":"2025-12-12","current":-6.031742,"twenty":-4.3315,"median":-2.319571,"eighty":-2.109405,"marketCap":457151721},{"date":"2025-12-19","current":-5.856703,"twenty":-5.07234,"median":-2.333015,"eighty":-2.111789,"marketCap":443885358},{"date":"2025-12-26","current":-6.660935,"twenty":-5.750734,"median":-2.336346,"eighty":-2.112399,"marketCap":504838920},{"date":"2026-01-02","current":-6.258819,"twenty":-5.908741,"median":-2.336346,"eighty":-2.11442,"marketCap":474362139},{"date":"2026-01-09","current":-6.585243,"twenty":-6.05445,"median":-2.344838,"eighty":-2.11744,"marketCap":499102115},{"date":"2026-01-16","current":-10.175903,"twenty":-6.388442,"median":-2.355734,"eighty":-2.117456,"marketCap":771241845},{"date":"2026-01-23","current":-10.411813,"twenty":-6.562534,"median":-2.368016,"eighty":-2.117456,"marketCap":789121720},{"date":"2026-01-30","current":-10.521991,"twenty":-6.660935,"median":-2.37516,"eighty":-2.117837,"marketCap":797472215},{"date":"2026-02-06","current":-11.006774,"twenty":-8.674889,"median":-2.403126,"eighty":-2.119987,"marketCap":834214390},{"date":"2026-02-13","current":-10.984738,"twenty":-9.153966,"median":-2.415588,"eighty":-2.124502,"marketCap":832544291},{"date":"2026-02-20","current":-11.094916,"twenty":-9.298497,"median":-2.422129,"eighty":-2.13258,"marketCap":840894786},{"date":"2026-02-27","current":-12.295855,"twenty":-9.537248,"median":-2.429257,"eighty":-2.136658,"marketCap":931915175},{"date":"2026-03-06","current":-11.22713,"twenty":-9.787979,"median":-2.458744,"eighty":-2.147751,"marketCap":850915379},{"date":"2026-03-13","current":-10.954439,"twenty":-10.064753,"median":-2.474292,"eighty":-2.150267,"marketCap":830247905},{"date":"2026-03-20","current":-11.590717,"twenty":-10.152544,"median":-2.496444,"eighty":-2.150267,"marketCap":878472010},{"date":"2026-03-27","current":-8.946976,"twenty":-10.175903,"median":-2.526002,"eighty":-2.154686,"marketCap":721170986},{"date":"2026-04-02","current":-9.761839,"twenty":-10.157216,"median":-2.545959,"eighty":-2.157168,"marketCap":786853020},{"date":"2026-04-10","current":-9.794874,"twenty":-10.109042,"median":-2.572155,"eighty":-2.15903,"marketCap":789515805},{"date":"2026-04-17","current":-9.354407,"twenty":-10.088448,"median":-2.581791,"eighty":-2.159654,"marketCap":754012003},{"date":"2026-04-24","current":-9.492053,"twenty":-10.157216,"median":-2.612676,"eighty":-2.159732,"marketCap":765106941},{"date":"2026-05-01","current":-9.281102,"twenty":-10.117474,"median":-2.677432,"eighty":-2.159732,"marketCap":748103216},{"date":"2026-05-08","current":-9.815385,"twenty":-10.117474,"median":-2.685566,"eighty":-2.162275,"marketCap":791169098},{"date":"2026-05-15","current":-9.250894,"twenty":-10.100274,"median":-2.711219,"eighty":-2.168441,"marketCap":831932916},{"date":"2026-05-22","current":-8.274644,"twenty":-10.088448,"median":-2.728907,"eighty":-2.172379,"marketCap":744138767},{"date":"2026-05-29","current":-8.427879,"twenty":-10.073417,"median":-2.779442,"eighty":-2.173018,"marketCap":757919114},{"date":"2026-06-05","current":-8.413049,"twenty":-10.064858,"median":-2.893147,"eighty":-2.175699,"marketCap":756585532},{"date":"2026-06-12","current":-8.131296,"twenty":-9.999175,"median":-2.971476,"eighty":-2.177486,"marketCap":731247474},{"date":"2026-06-18","current":-9.881131,"twenty":-10.021034,"median":-3.072547,"eighty":-2.177486,"marketCap":888610152},{"date":"2026-06-26","current":-11.18115,"twenty":-10.10449,"median":-3.377371,"eighty":-2.17969,"marketCap":1005520843},{"date":"2026-07-02","current":-11.991808,"twenty":-10.16483,"median":-3.4182,"eighty":-2.183022,"marketCap":1078423326},{"date":"2026-07-10","current":-12.30322,"twenty":-10.247258,"median":-3.447686,"eighty":-2.183492,"marketCap":1106428549},{"date":"2026-07-17","current":-10.953771,"twenty":-10.359979,"median":-3.495318,"eighty":-2.185281,"marketCap":985072585},{"date":"2026-07-24","current":-10.825252,"twenty":-10.509871,"median":-3.543352,"eighty":-2.186883,"marketCap":973514874},{"date":"2026-07-31","current":-12.283448,"twenty":-10.632169,"median":-3.606461,"eighty":-2.188179,"marketCap":1104650439},{"date":"2026-08-07","current":-5.30342,"twenty":-10.612701,"median":-3.697103,"eighty":-2.190009,"marketCap":500982312},{"date":"2026-08-14","current":-5.067589,"twenty":-10.521991,"median":-3.898161,"eighty":-2.190009,"marketCap":478704760},{"date":"2026-08-21","current":-4.708048,"twenty":-10.461393,"median":-3.973853,"eighty":-2.193232,"marketCap":444741048},{"date":"2026-08-28","current":-4.897536,"twenty":-10.411813,"median":-4.092123,"eighty":-2.193232,"marketCap":462640842},{"date":"2026-09-04","current":-4.615733,"twenty":-10.411209,"median":-4.290815,"eighty":-2.195055,"marketCap":436020635},{"date":"2026-09-09","current":-4.564717,"twenty":-10.391619,"median":-4.342854,"eighty":-2.196347,"marketCap":431201460}],"updateTime":1789113364984},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIOA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633645198","title":"Bioage Labs Q1 EPS $(0.52) Beats $(0.64) Estimate, Sales $2.772M Beat $1.083M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633645198","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633645198?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:09","pubTimestamp":1778245796,"startTime":"0","endTime":"0","summary":"Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 44.44 percent decrease over losses of $(0.36) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52407662/bioage-labs-q1-eps-0-52-beats-0-64-estimate-sales-2-772m-beat-1-083m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633961451","title":"BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2633961451","media":"Reuters","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633961451?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:09","pubTimestamp":1778245783,"startTime":"0","endTime":"0","summary":"BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaborationOverviewUS biopharma firm's Q1 collaboration revenue rose, beating analyst expectationsNet loss widened on higher R&D expe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL1N41L0K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633714459","title":"Bioage Labs Inc Q1 Collaboration Revenue USD 2.772 Million VS. Ibes Estimate USD 1.32 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633714459","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633714459?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:00","pubTimestamp":1778245201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nPLXA6847F:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459717","title":"Bioage Labs Inc Q1 EPS USD -0.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459717?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:00","pubTimestamp":1778245201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nPLXA6847F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633229451","title":"BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633229451","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633229451?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:00","pubTimestamp":1778245200,"startTime":"0","endTime":"0","summary":"Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3291115/0/en/BioAge-Labs-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633969505","title":"BioAge hosts R&D Day webcast on BGE-102 NLRP3 inhibitor program","url":"https://stock-news.laohu8.com/highlight/detail?id=2633969505","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633969505?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:39","pubTimestamp":1777927157,"startTime":"0","endTime":"0","summary":"BioAge Labs to host an R&D Day webcast on May 8, 2026, starting 12:30 PM ET, focused on NLRP3 inhibition.Event set to feature Phase 1 clinical data for BGE-102, an oral NLRP3 inflammasome inhibitor.Company to outline development rationale for BGE-102 in atherosclerotic cardiovascular disease, plus retinal disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL1Zsc7l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4007","BK4588","SG9999014005.SGD","BIOA","SG9999014021.USD","NDAQ","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","SG9999014039.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629057230","title":"BioAge Labs announces annual shareholder meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2629057230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629057230?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:06","pubTimestamp":1776801989,"startTime":"0","endTime":"0","summary":"BioAge Labs schedules 2026 annual shareholder meeting for June 10, 2026, held virtually.Shareholders will vote on election of three Class II directors to three-year terms.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL4y6hXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629054921","title":"Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Geron (GERN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629054921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629054921?lang=en_us&edition=fundamental","pubTime":"2026-04-22 02:40","pubTimestamp":1776796806,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on BioAge Labs, Inc. (BIOA) and Geron (GERN) with neutral ratings, indicating that the experts are neith...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioage-labs-inc-bioa-and-geron-gern-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioage-labs-inc-bioa-and-geron-gern-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA","XBI","HCSG","LABU","BK4137","BK4139","LU0029874061.USD","LU0128526141.USD","BK4581","BK4588","GERN","XLV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629055586","title":"BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2629055586","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629055586?lang=en_us&edition=fundamental","pubTime":"2026-04-21 23:35","pubTimestamp":1776785720,"startTime":"0","endTime":"0","summary":"Needham analyst Joseph Stringer maintained a Buy rating on BioAge Labs, Inc. today and set a price target of $50.00. Joseph Stringer has given his ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bioage-labs-bioa-phase-1-bge-102-data-reinforce-best-in-class-nlrp3-potential-and-de-risk-2026-cardiovascular-phase-2-supporting-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bioage-labs-bioa-phase-1-bge-102-data-reinforce-best-in-class-nlrp3-potential-and-de-risk-2026-cardiovascular-phase-2-supporting-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","CSII"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629031631","title":"BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2629031631","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629031631?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:30","pubTimestamp":1776774633,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) reported results from the Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant small molecule NLRP3 inh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-reports-results-for-phase-1-trial-of-bge-102-to-initiate-phase-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-reports-results-for-phase-1-trial-of-bge-102-to-initiate-phase-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629303660","title":"BioAge Shares Rise on Positive Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2629303660","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629303660?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:58","pubTimestamp":1776772680,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs were higher after the company shared positive data for a trial of its drug as a treatment for inflammation.The stock gained 9% to $20.49 in pre-market trading Tuesday. Through Monday's close, shares were up 42% this year.In a Phase 1 clinical trial, the drug BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein, a test of inflammation levels and cardiovascular risk.Patients dosed with 60 milligrams achieved reductions that were comparable to those who received a higher dose of 120 milligrams, the biopharmaceutical company said.Based on the results, BioAge plans to start a dose-ranging Phase 2 trial studying the drug as a treatment for cardiovascular risk. It intends to initiate the trial in the first half of 2026, with data anticipated in the second half of the year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"BioAge Shares Rise on Positive Trial Data","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629357730","title":"BioAge Labs Says Drug Candidate Shows 'Best-in-Class Reductions' in Inflammatory Biomarkers in Phase 1 Trial With Obese Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2629357730","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629357730?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:44","pubTimestamp":1776771882,"startTime":"0","endTime":"0","summary":"BioAge Labs  said Tuesday its experimental BGE-102 drug demonstrated \"best-in-class reductions\" in inflammatory biomarkers during a phase 1 trial involving participants with obesity.Both the 60 mg and 120 mg daily doses lowered high-sensitivity C-reactive protein levels by at least 85% while maintaining a favorable safety profile, the company said.The company plans to begin a phase 2 study focused on cardiovascular risk during H1, with initial data expected by the end of the year.BioAge also intends to launch a separate proof-of-concept trial for diabetic macular edema in mid-2026 to evaluate the treatment's effect on retinal diseases.Shares of the company rose 9% in Tuesday's premarket activity.Price: 20.49, Change: +1.69, Percent Change: +8.99","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703382","title":"Bioage Labs: Reports Positive Phase 1 Data for Bge-102","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629703382?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769454,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41409Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603331","title":"Bioage Labs Inc - Phase 2 Cardiovascular Risk Trial to Initiate Mid-2026, Results Expected End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603331?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769454,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41409Y:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629333180","title":"Bioage Labs Inc - Bge-102 Well Tolerated Across All Dose Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2629333180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629333180?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769454,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41409Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033876","title":"Bioage Labs Inc - Bge-102 Achieves ≥85% Median Hscrp Reductions at 120 Mg and 60 Mg Doses in Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629033876?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:04","pubTimestamp":1776769454,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN41409Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629038085","title":"BioAge reports Phase 1 data for BGE-102, showing 85% hsCRP reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2629038085","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629038085?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:02","pubTimestamp":1776769339,"startTime":"0","endTime":"0","summary":"BioAge reported positive Phase 1 results for BGE-102, an oral NLRP3 inhibitor, showing strong reductions in inflammation markers in participants with obesity and elevated baseline inflammation.Data released included a newly disclosed 60 mg once-daily cohort, with outcomes described as comparable to previously reported results from a higher-dose group.BGE-102 was described as well tolerated across evaluated doses, supporting continued investment to advance the program.BioAge plans to start a Phase 2 dose-ranging cardiovascular risk proof-of-concept trial in first half of 2026, with results expected in second half of 2026.Company also plans a Phase 1b/2a proof-of-concept trial in diabetic macular edema in mid-2026, with results expected mid-2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLbVVjnM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","NDAQ","LU2095319765.USD","BK4112","SG9999014039.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014021.USD","SG9999014013.SGD","BK4585","BK4007","BIOA","IE00BKPKM429.USD","LU0314104364.USD","BK4588","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627465541","title":"BioAge Labs to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627465541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627465541?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:30","pubTimestamp":1776112252,"startTime":"0","endTime":"0","summary":"BioAge Labs will present at 25th Annual Needham Virtual Healthcare Conference on April 13-16, 2026.CEO Kristen Fortney is scheduled for fireside chat on April 16, 2026, from 3:00 PM to 3:30 PM EDT.CFO Dov Goldstein, Chief Strategy Officer BJ Sullivan will hold one-on-one investor meetings during conference.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLbrDQwK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BIOA","LU0314104364.USD","BK4585","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4112","SG9999014039.USD","SG9999014021.USD","LU2210150020.SGD","BK4007","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","NDAQ","BK4588","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624966489","title":"BioAge Labs CMO Paul D. Rubin disposes of common shares worth $0.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624966489","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624966489?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:07","pubTimestamp":1775246878,"startTime":"0","endTime":"0","summary":"BioAge Labs Chief Medical Officer Paul D. Rubin reported sale of 8,820 shares on April 1, 2026.Rubin ended day with 0 shares beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL8p1H5j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioAge Labs CMO Paul D. Rubin disposes of common shares worth $0.2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823007","title":"Needham Initiates BioAge Labs at Buy With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823007","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823007?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:22","pubTimestamp":1774610527,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) has an average rating of overweight and mean price target of $53.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":100,"code":"91000000","status":"200"}]}}